Jason A. Zell
University of California, Irvine
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Jason A. Zell as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:36 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT01349881 · S0820, Adenoma and Second Primary Prevention TrialSWOG Cancer Research Network · active not recruiting · Colorectal Neoplasms · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:36 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 1 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Advancing novel cancer preventive and therapeutic strategies across the modern NCI clinical trial networksR50CA285412 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · fiscal years 2024 to 2026 · $196,267 awarded in 2026Same name and institution; not confirmed by an ID
- Enhancing Electronic Health Systems to Decrease the Burden of Colon Cancer, Lung Cancer, Obesity, Vaccine-Preventable Illness, and Liver Cancer (CLOVER)R61AG068948 · NIA · UNIVERSITY OF CALIFORNIA AT DAVIS · fiscal years 2020 to 2021 · $293,756 awarded in 2021Same name and institution; not confirmed by an ID
- Risk reduction through polyamine inhibition among colorectal carcinoma patientsK23CA133142 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · fiscal years 2009 to 2012 · $179,143 awarded in 2012Same name and institution; not confirmed by an ID
- PHASE IIA CLINICAL BIOMARKER TRIAL OF ASPIRIN AND ARGININE RESTRICTION IN COLONM01RR000827 · NCRR · UNIVERSITY OF CALIFORNIA, SAN DIEGO · fiscal years 2010 · $1,208 awarded in 2010Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- SWOG Community Clinical Oncology Program Research BaseU10CA037429 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI CHARLES D. BLANKE, FRANK L. MEYSKENS · fiscal years 1985 to 2014Named on NCT01349881
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:36 UTC. The ranking covers the 200 most relevant of 8 PubMed records, and a shared surname and initials can bring in a namesake. All 8 on PubMed
- Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas.Cancer Prev Res (Phila) · 200949 citationsRCR 1.1
- Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma.Gastroenterology · 201045 citationsRCR 1.0
- Ornithine decarboxylase-1 polymorphism, chemoprevention with eflornithine and sulindac, and outcomes among colorectal adenoma patients.J Natl Cancer Inst · 201029 citationsRCR 0.6
- A Phase IIa Trial of Metformin for Colorectal Cancer Risk Reduction among Individuals with History of Colorectal Adenomas and Elevated Body Mass Index.Cancer Prev Res (Phila) · 202028 citationsRCR 1.3
- Role of obesity in a randomized placebo-controlled trial of difluoromethylornithine (DFMO) + sulindac for the prevention of sporadic colorectal adenomas.Cancer Causes Control · 20126 citationsRCR 0.2
- Phase IIA trial testing erlotinib as an intervention against intraductal pancreatic mucinous neoplasms.Cancer Prev Res (Phila) · 20115 citationsRCR 0.1
- A phase IIa randomized, double-blind trial of erlotinib in inhibiting epidermal growth factor receptor signaling in aberrant crypt foci of the colorectum.Cancer Prev Res (Phila) · 20152 citationsRCR 0.0
- A Phase 1 Study of Cabozantinib and Trifluridine/Tipiracil in Metastatic Colorectal Adenocarcinoma.Clin Colorectal Cancer · 20241 citationsRCR 0.1